November 5, 2026 · Phase 3 readout
PCVX Phase 3 readout: a negative outcome, -5.7%
On November 5, 2026, 31-valent pneumococcal conjugate vaccine — Vaxcyte, Inc. (Pneumococcal Vaccines) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -5.7% in the window around the event. It had already run -9.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$65.68
1d before
$61.92
Event day
$61.92
1d after
$61.92
5d after
Our prediction vs. the result
CatalystAlert called this one up (+2.6% expected); the stock actually moved -5.7%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
-9.1%
30-day run-up
5833%
30-day volatility
0.6×
volume spike